- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT04490681
Validation of ERTugliflozin for Inhibiting Cardiac Fibrosis Using Cardiac MRI and Laboratory Parameters in Korean Heart Failure Patients With Nonischemic Cardiomyopathy(VERTICAL)
Based on recent studies demonstrating SGLT2 inhibitors' favorable effects on cardiovascular outcomes especially for heart failure, the investigators hypothesize that sodium-glucose co-transporter-2 (SGLT2) inhibitor, ertugliflozin, is effective on reducing cardiac fibrosis in patients with nonischemic cardiomyopathy so the investigators try to examine this hypothesis in a single-center, double-blind, randomized controlled study using cardiac magnetic resonance (CMR).
This study is a prospective, single-center, randomized, double-blind, two arm parallel group, placebo-controlled clinical trial involving patients with nonischemic cardiomyopathy. Patients meeting inclusion criteria without any exclusion criteria will be randomized 1:1 to ertugliflozin or placebo therapy, and cardiovascular functional assessment and clinical event follow-up will be undertaken.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Studientyp
Einschreibung (Voraussichtlich)
Phase
- Phase 3
Kontakte und Standorte
Studienkontakt
- Name: Seok-Min Kang
- Telefonnummer: 82-2-2228-8450
- E-Mail: smkang@yuhs.ac
Studienorte
-
-
-
Seoul, Korea, Republik von
- Severance Hospiatal
-
Kontakt:
- Seok-Min Kang
- Telefonnummer: 82-2-2228-8450
- E-Mail: smkang@yuhs.ac
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Patients must agree to the study protocol and provide written informed consent
- Outpatients ≥ 19 years, <75 years of age, male or female
- Non-diabetic or type 2 DM patients with HbA1c 7.0-10.5%
- Patients with nonischemic cardiomyopathy (LVEF ≤40%)
- Exclusion of ischemic origin cardiomyopathy using coronary angiography or CT angiography or SPECT scan (e.g. significant stenosis of proximal LAD or left main & myocardial infarction)
- Dyspnea of NYHA functional class II or III
- NT-proBNP ≥ 400 pg/ml (≥ 900 pg/ml if atrial fibrillation or atrial flutter)
- Titration of HF medications should be completed and patients must take a stable, optimized dose of a β-blocker and an ACE inhibitor (or ARB or ARNI if indicated) for at least 4 weeks prior to study entry
Exclusion Criteria:
- History of hypersensitivity or allergy to the study drug, drugs of similar chemical classes, or SGLT-2 as well as known or suspected contraindications to the study drug
- Current use or prior use of a SGLT-2 inhibitor or combined SGLT-1 and 2 inhibitor
- Known history of angioedema
- Current acute decompensated heart failure or dyspnea of NYHA functional class IV
- Medical history of hospitalization within 6 weeks
- Acute coronary syndrome, stroke, major CV surgery, PCI within 3 months
- Substantial myocardial ischemia requiring coronary revascularization therapy or a plan of coronary revascularization within 6 months
- A plan of heart transplantation or implantation of cardiac resynchronization therapy
- Symptomatic hypotension and/or a SBP < 95 mmHg at screening
- Estimated GFR < 30 mL/min/1.73m2
- History of ketoacidosis
- Symptomatic peripheral artery disease and history of lower limb amputation
- Evidence of hepatic disease as determined by any one of the following: AST or ALT values exceeding 3 x upper limit of normal (ULN) at screening visit (Visit 0), history of hepatic encephalopathy, history of esophageal varices, or history of portacaval shunt.
- History of severe pulmonary disease
- Significant mitral & aortic valve disease (e.g. moderate to severe, severe degree)
- Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using a barrier method plus a hormonal method
- Pregnant or nursing (lactating) women
- Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgment of the investigator, would preclude safe completion of the study
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Vervierfachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Placebo-Komparator: Placebo
|
Placebo-Gruppe
|
Experimental: Ertugliflozin
Ertugliflozin 5mg
|
Fixed dose Ertugliflozin (5mg)
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
The ECV value change in CMR after Drug (Ertugliflozin or Placebo) administration
Zeitfenster: Baseline
|
The ECV value change in MRI from baseline to End of trial (48 weeks)
|
Baseline
|
The ECV value change in CMR after Drug (Ertugliflozin or Placebo) administration
Zeitfenster: 48 Weeks after drug administration
|
The ECV value change in MRI from baseline to End of trial (48 weeks)
|
48 Weeks after drug administration
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
CMR parameters : ECV (%)
Zeitfenster: baseline
|
CMR parameters : the changes of myocardial fibrosis markers (ECV, Native T1), ventricular muscle mass marker (left & right ventricular (LV & RV) mass index), ventricular functional markers (LV & RV ejection fraction, cine-base cardiac strain), and ventricular remodeling markers (LV & RV end-systolic volume, LV & RV end-diastolic volume).
These parameters represent myocardial fibrotic change, ventricular remodelling, systolic function.
|
baseline
|
CMR parameters : ECV (%)
Zeitfenster: 12 weeks after drug administration
|
CMR parameters : the changes of myocardial fibrosis markers (ECV, Native T1), ventricular muscle mass marker (left & right ventricular (LV & RV) mass index), ventricular functional markers (LV & RV ejection fraction, cine-base cardiac strain), and ventricular remodeling markers (LV & RV end-systolic volume, LV & RV end-diastolic volume).
These parameters represent myocardial fibrotic change, ventricular remodelling, systolic function.
|
12 weeks after drug administration
|
CMR parameters : ECV (%)
Zeitfenster: 48 weeks after drug administration
|
CMR parameters : the changes of myocardial fibrosis markers (ECV, Native T1), ventricular muscle mass marker (left & right ventricular (LV & RV) mass index), ventricular functional markers (LV & RV ejection fraction, cine-base cardiac strain), and ventricular remodeling markers (LV & RV end-systolic volume, LV & RV end-diastolic volume).
These parameters represent myocardial fibrotic change, ventricular remodelling, systolic function.
|
48 weeks after drug administration
|
CMR parameters : Native T1 (ms)
Zeitfenster: baseline
|
CMR parameters : the changes of myocardial fibrosis markers (ECV, Native T1), ventricular muscle mass marker (left & right ventricular (LV & RV) mass index), ventricular functional markers (LV & RV ejection fraction, cine-base cardiac strain), and ventricular remodeling markers (LV & RV end-systolic volume, LV & RV end-diastolic volume).
These parameters represent myocardial fibrotic change, ventricular remodelling, systolic function.
|
baseline
|
CMR parameters : Native T1 (ms)
Zeitfenster: 12 weeks after drug administration
|
CMR parameters : the changes of myocardial fibrosis markers (ECV, Native T1), ventricular muscle mass marker (left & right ventricular (LV & RV) mass index), ventricular functional markers (LV & RV ejection fraction, cine-base cardiac strain), and ventricular remodeling markers (LV & RV end-systolic volume, LV & RV end-diastolic volume).
These parameters represent myocardial fibrotic change, ventricular remodelling, systolic function.
|
12 weeks after drug administration
|
CMR parameters : Native T1 (ms)
Zeitfenster: 48 weeks after drug administration
|
CMR parameters : the changes of myocardial fibrosis markers (ECV, Native T1), ventricular muscle mass marker (left & right ventricular (LV & RV) mass index), ventricular functional markers (LV & RV ejection fraction, cine-base cardiac strain), and ventricular remodeling markers (LV & RV end-systolic volume, LV & RV end-diastolic volume).
These parameters represent myocardial fibrotic change, ventricular remodelling, systolic function.
|
48 weeks after drug administration
|
CMR parameters : left & right ventricular (LV & RV) mass index (g/m2)
Zeitfenster: Baseline
|
CMR parameters : the changes of myocardial fibrosis markers (ECV, Native T1), ventricular muscle mass marker (left & right ventricular (LV & RV) mass index), ventricular functional markers (LV & RV ejection fraction, cine-base cardiac strain), and ventricular remodeling markers (LV & RV end-systolic volume, LV & RV end-diastolic volume).
These parameters represent myocardial fibrotic change, ventricular remodelling, systolic function.
|
Baseline
|
CMR parameters : left & right ventricular (LV & RV) mass index (g/m2)
Zeitfenster: 12 weeks after drug administration
|
CMR parameters : the changes of myocardial fibrosis markers (ECV, Native T1), ventricular muscle mass marker (left & right ventricular (LV & RV) mass index), ventricular functional markers (LV & RV ejection fraction, cine-base cardiac strain), and ventricular remodeling markers (LV & RV end-systolic volume, LV & RV end-diastolic volume).
These parameters represent myocardial fibrotic change, ventricular remodelling, systolic function.
|
12 weeks after drug administration
|
CMR parameters : left & right ventricular (LV & RV) mass index (g/m2)
Zeitfenster: 48 weeks after drug administration
|
CMR parameters : the changes of myocardial fibrosis markers (ECV, Native T1), ventricular muscle mass marker (left & right ventricular (LV & RV) mass index), ventricular functional markers (LV & RV ejection fraction, cine-base cardiac strain), and ventricular remodeling markers (LV & RV end-systolic volume, LV & RV end-diastolic volume).
These parameters represent myocardial fibrotic change, ventricular remodelling, systolic function.
|
48 weeks after drug administration
|
CMR parameters : LV & RV ejection fraction (%)
Zeitfenster: Baseline
|
CMR parameters : the changes of myocardial fibrosis markers (ECV, Native T1), ventricular muscle mass marker (left & right ventricular (LV & RV) mass index), ventricular functional markers (LV & RV ejection fraction, cine-base cardiac strain), and ventricular remodeling markers (LV & RV end-systolic volume, LV & RV end-diastolic volume).
These parameters represent myocardial fibrotic change, ventricular remodelling, systolic function.
|
Baseline
|
CMR parameters : LV & RV ejection fraction (%)
Zeitfenster: 12 weeks after drug administration
|
CMR parameters : the changes of myocardial fibrosis markers (ECV, Native T1), ventricular muscle mass marker (left & right ventricular (LV & RV) mass index), ventricular functional markers (LV & RV ejection fraction, cine-base cardiac strain), and ventricular remodeling markers (LV & RV end-systolic volume, LV & RV end-diastolic volume).
These parameters represent myocardial fibrotic change, ventricular remodelling, systolic function.
|
12 weeks after drug administration
|
CMR parameters : LV & RV ejection fraction (%)
Zeitfenster: 48 weeks after drug administration
|
CMR parameters : the changes of myocardial fibrosis markers (ECV, Native T1), ventricular muscle mass marker (left & right ventricular (LV & RV) mass index), ventricular functional markers (LV & RV ejection fraction, cine-base cardiac strain), and ventricular remodeling markers (LV & RV end-systolic volume, LV & RV end-diastolic volume).
These parameters represent myocardial fibrotic change, ventricular remodelling, systolic function.
|
48 weeks after drug administration
|
CMR parameters : LV & RV end-systolic volume, LV & RV end-diastolic volume (ml)
Zeitfenster: Baseline
|
CMR parameters : the changes of myocardial fibrosis markers (ECV, Native T1), ventricular muscle mass marker (left & right ventricular (LV & RV) mass index), ventricular functional markers (LV & RV ejection fraction, cine-base cardiac strain), and ventricular remodeling markers (LV & RV end-systolic volume, LV & RV end-diastolic volume).
These parameters represent myocardial fibrotic change, ventricular remodelling, systolic function.
|
Baseline
|
CMR parameters : LV & RV end-systolic volume, LV & RV end-diastolic volume (ml)
Zeitfenster: 12 weeks after drug administration
|
CMR parameters : the changes of myocardial fibrosis markers (ECV, Native T1), ventricular muscle mass marker (left & right ventricular (LV & RV) mass index), ventricular functional markers (LV & RV ejection fraction, cine-base cardiac strain), and ventricular remodeling markers (LV & RV end-systolic volume, LV & RV end-diastolic volume).
These parameters represent myocardial fibrotic change, ventricular remodelling, systolic function.
|
12 weeks after drug administration
|
CMR parameters : LV & RV end-systolic volume, LV & RV end-diastolic volume (ml)
Zeitfenster: 48 weeks after drug administration
|
CMR parameters : the changes of myocardial fibrosis markers (ECV, Native T1), ventricular muscle mass marker (left & right ventricular (LV & RV) mass index), ventricular functional markers (LV & RV ejection fraction, cine-base cardiac strain), and ventricular remodeling markers (LV & RV end-systolic volume, LV & RV end-diastolic volume).
These parameters represent myocardial fibrotic change, ventricular remodelling, systolic function.
|
48 weeks after drug administration
|
CMR parameters : cine-base cardiac strain (%)
Zeitfenster: Baseline
|
CMR parameters : the changes of myocardial fibrosis markers (ECV, Native T1), ventricular muscle mass marker (left & right ventricular (LV & RV) mass index), ventricular functional markers (LV & RV ejection fraction, cine-base cardiac strain), and ventricular remodeling markers (LV & RV end-systolic volume, LV & RV end-diastolic volume).
These parameters represent myocardial fibrotic change, ventricular remodelling, systolic function.
|
Baseline
|
CMR parameters : cine-base cardiac strain (%)
Zeitfenster: 12 weeks after drug administration
|
CMR parameters : the changes of myocardial fibrosis markers (ECV, Native T1), ventricular muscle mass marker (left & right ventricular (LV & RV) mass index), ventricular functional markers (LV & RV ejection fraction, cine-base cardiac strain), and ventricular remodeling markers (LV & RV end-systolic volume, LV & RV end-diastolic volume).
These parameters represent myocardial fibrotic change, ventricular remodelling, systolic function.
|
12 weeks after drug administration
|
CMR parameters : cine-base cardiac strain (%)
Zeitfenster: 48 weeks after drug administration
|
CMR parameters : the changes of myocardial fibrosis markers (ECV, Native T1), ventricular muscle mass marker (left & right ventricular (LV & RV) mass index), ventricular functional markers (LV & RV ejection fraction, cine-base cardiac strain), and ventricular remodeling markers (LV & RV end-systolic volume, LV & RV end-diastolic volume).
These parameters represent myocardial fibrotic change, ventricular remodelling, systolic function.
|
48 weeks after drug administration
|
Biomarkers : NT-proBNP, hsTn, soluble ST2, galectin-3, IGFBP7
Zeitfenster: baseline
|
The change in degree of NT-proBNP, hsTn, soluble ST2, galectin-3, IGFBP7 after drug administration.
|
baseline
|
Biomarkers : NT-proBNP, hsTn, soluble ST2, galectin-3, IGFBP7
Zeitfenster: 12 weeks after drug administration
|
The change in degree of NT-proBNP, hsTn, soluble ST2, galectin-3, IGFBP7 after drug administration.
|
12 weeks after drug administration
|
Biomarkers : NT-proBNP, hsTn, soluble ST2, galectin-3, IGFBP7
Zeitfenster: 24 weeks after drug administration
|
The change in degree of NT-proBNP, hsTn, soluble ST2, galectin-3, IGFBP7 after drug administration.
|
24 weeks after drug administration
|
Biomarkers : NT-proBNP, hsTn, soluble ST2, galectin-3, IGFBP7
Zeitfenster: 48 weeks after drug administration
|
The change in degree of NT-proBNP, hsTn, soluble ST2, galectin-3, IGFBP7 after drug administration.
|
48 weeks after drug administration
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Voraussichtlich)
Primärer Abschluss (Voraussichtlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 4-2020-0484
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Placebo
-
SamA Pharmaceutical Co., LtdUnbekanntAkute Bronchitis | Akute Infektion der oberen AtemwegeKorea, Republik von
-
National Institute on Drug Abuse (NIDA)AbgeschlossenCannabiskonsumVereinigte Staaten
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyAbgeschlossenMännliche Probanden mit Typ-II-Diabetes (T2DM)Deutschland
-
Instituto de Investigación Hospital Universitario...Creaciones Aromáticas Industriales, S.A. (CARINSA)Abgeschlossen
-
Soroka University Medical CenterAbgeschlossen
-
Regado Biosciences, Inc.AbgeschlossenGesunder FreiwilligerVereinigte Staaten
-
Longeveron Inc.BeendetHypoplastisches LinksherzsyndromVereinigte Staaten
-
Texas A&M UniversityNutraboltAbgeschlossenGlucose and Insulin Response
-
Heptares Therapeutics LimitedAbgeschlossenPharmakokinetik | SicherheitsproblemeVereinigtes Königreich